A case of congenital partial lipodystrophy without lamin A/C and PPARγ mutations (Köbberling type or variety): A long-term follow-up regarding the efficacy of thiazolidinediones (pioglitazone)

Haruka Sasaki, Kumiko Ohkubo, Hiroyuki Tominaga, Kenichi Tomita, Kenzou Iino, Yuji Tajiri, Hiroshi Maegawa, Atsunori Kashiwagi, Junko Ono, Shuzo Kumagai, Keiko Uezono, Fumihiko Hara

Research output: Contribution to journalArticle

Abstract

Complex genotype/phenotype relationships have been reported in congenital partial lipodystrophy. The patient was a 33-year-old female with progeroid features and hyperinsulinemia, insulin resistance associated with metabolic abnormalities including not only diabetes, hypertension, fatty liver, hirsutism, polycystic ovary syndrome, acanthosis nigricans, as well as a also short stature and a sensorineural deafness. Her body fat distribution was the characteristic pattern of "partial lipodystrohy" which showed a generalized subcutaneous fat loss, but an excessive accumulation of intraabdominal fat Low fasting plasma leptin and adiponectin levels were observed. No Lamin A/C or PPARγ mutations were identified. Normal insulin receptor binding and an abnormality in the post IRS-1 signaling pathway were found by a primary fibroblast culture. She was tentatively diagnosed to have either the sporadic Köbberling type or a variety of congenital [familial]partial lipodystropy (referred to in publications as the "FPLD1"). We herein present our long-term experience of treating this case with pioglitazone. Both subcutaneous and visceral fat increased following this treatment in addition the leptin and adiponectin levels also increased. An increased insulin sensitivity and improvements in both glucose intolerance and liver dysfunction were also observed during the follow-up period. This case therefore demonstrated the benefits of PPARγ-agonists, pioglitazone on metabolic abnormalities in a patient with Köbberling type of FPLD without any adverse side effects. A large series of pioglitazone treatment cases should therefore be studied to elucidate the efficacy of this treatment regimen for genetically different types of FPLD.

Original languageEnglish
Pages (from-to)849-860
Number of pages12
JournalJournal of the Japan Diabetes Society
Volume51
Issue number9
Publication statusPublished - Oct 24 2008

Fingerprint

pioglitazone
Lamin Type A
Lipodystrophy
Thiazolidinediones
Peroxisome Proliferator-Activated Receptors
Subcutaneous Fat
Adiponectin
Leptin
Mutation
Insulin Resistance
Acanthosis Nigricans
Body Fat Distribution
Hirsutism
Glucose Intolerance
Intra-Abdominal Fat
Polycystic Ovary Syndrome
Insulin Receptor
Hyperinsulinism
Deafness
Fatty Liver

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A case of congenital partial lipodystrophy without lamin A/C and PPARγ mutations (Köbberling type or variety) : A long-term follow-up regarding the efficacy of thiazolidinediones (pioglitazone). / Sasaki, Haruka; Ohkubo, Kumiko; Tominaga, Hiroyuki; Tomita, Kenichi; Iino, Kenzou; Tajiri, Yuji; Maegawa, Hiroshi; Kashiwagi, Atsunori; Ono, Junko; Kumagai, Shuzo; Uezono, Keiko; Hara, Fumihiko.

In: Journal of the Japan Diabetes Society, Vol. 51, No. 9, 24.10.2008, p. 849-860.

Research output: Contribution to journalArticle

Sasaki, Haruka ; Ohkubo, Kumiko ; Tominaga, Hiroyuki ; Tomita, Kenichi ; Iino, Kenzou ; Tajiri, Yuji ; Maegawa, Hiroshi ; Kashiwagi, Atsunori ; Ono, Junko ; Kumagai, Shuzo ; Uezono, Keiko ; Hara, Fumihiko. / A case of congenital partial lipodystrophy without lamin A/C and PPARγ mutations (Köbberling type or variety) : A long-term follow-up regarding the efficacy of thiazolidinediones (pioglitazone). In: Journal of the Japan Diabetes Society. 2008 ; Vol. 51, No. 9. pp. 849-860.
@article{bd4b777f796640fd8a692648ccad26b5,
title = "A case of congenital partial lipodystrophy without lamin A/C and PPARγ mutations (K{\"o}bberling type or variety): A long-term follow-up regarding the efficacy of thiazolidinediones (pioglitazone)",
abstract = "Complex genotype/phenotype relationships have been reported in congenital partial lipodystrophy. The patient was a 33-year-old female with progeroid features and hyperinsulinemia, insulin resistance associated with metabolic abnormalities including not only diabetes, hypertension, fatty liver, hirsutism, polycystic ovary syndrome, acanthosis nigricans, as well as a also short stature and a sensorineural deafness. Her body fat distribution was the characteristic pattern of {"}partial lipodystrohy{"} which showed a generalized subcutaneous fat loss, but an excessive accumulation of intraabdominal fat Low fasting plasma leptin and adiponectin levels were observed. No Lamin A/C or PPARγ mutations were identified. Normal insulin receptor binding and an abnormality in the post IRS-1 signaling pathway were found by a primary fibroblast culture. She was tentatively diagnosed to have either the sporadic K{\"o}bberling type or a variety of congenital [familial]partial lipodystropy (referred to in publications as the {"}FPLD1{"}). We herein present our long-term experience of treating this case with pioglitazone. Both subcutaneous and visceral fat increased following this treatment in addition the leptin and adiponectin levels also increased. An increased insulin sensitivity and improvements in both glucose intolerance and liver dysfunction were also observed during the follow-up period. This case therefore demonstrated the benefits of PPARγ-agonists, pioglitazone on metabolic abnormalities in a patient with K{\"o}bberling type of FPLD without any adverse side effects. A large series of pioglitazone treatment cases should therefore be studied to elucidate the efficacy of this treatment regimen for genetically different types of FPLD.",
author = "Haruka Sasaki and Kumiko Ohkubo and Hiroyuki Tominaga and Kenichi Tomita and Kenzou Iino and Yuji Tajiri and Hiroshi Maegawa and Atsunori Kashiwagi and Junko Ono and Shuzo Kumagai and Keiko Uezono and Fumihiko Hara",
year = "2008",
month = "10",
day = "24",
language = "English",
volume = "51",
pages = "849--860",
journal = "Journal of the Japan Diabetes Society",
issn = "0021-437X",
publisher = "Japan Diabetes Society",
number = "9",

}

TY - JOUR

T1 - A case of congenital partial lipodystrophy without lamin A/C and PPARγ mutations (Köbberling type or variety)

T2 - A long-term follow-up regarding the efficacy of thiazolidinediones (pioglitazone)

AU - Sasaki, Haruka

AU - Ohkubo, Kumiko

AU - Tominaga, Hiroyuki

AU - Tomita, Kenichi

AU - Iino, Kenzou

AU - Tajiri, Yuji

AU - Maegawa, Hiroshi

AU - Kashiwagi, Atsunori

AU - Ono, Junko

AU - Kumagai, Shuzo

AU - Uezono, Keiko

AU - Hara, Fumihiko

PY - 2008/10/24

Y1 - 2008/10/24

N2 - Complex genotype/phenotype relationships have been reported in congenital partial lipodystrophy. The patient was a 33-year-old female with progeroid features and hyperinsulinemia, insulin resistance associated with metabolic abnormalities including not only diabetes, hypertension, fatty liver, hirsutism, polycystic ovary syndrome, acanthosis nigricans, as well as a also short stature and a sensorineural deafness. Her body fat distribution was the characteristic pattern of "partial lipodystrohy" which showed a generalized subcutaneous fat loss, but an excessive accumulation of intraabdominal fat Low fasting plasma leptin and adiponectin levels were observed. No Lamin A/C or PPARγ mutations were identified. Normal insulin receptor binding and an abnormality in the post IRS-1 signaling pathway were found by a primary fibroblast culture. She was tentatively diagnosed to have either the sporadic Köbberling type or a variety of congenital [familial]partial lipodystropy (referred to in publications as the "FPLD1"). We herein present our long-term experience of treating this case with pioglitazone. Both subcutaneous and visceral fat increased following this treatment in addition the leptin and adiponectin levels also increased. An increased insulin sensitivity and improvements in both glucose intolerance and liver dysfunction were also observed during the follow-up period. This case therefore demonstrated the benefits of PPARγ-agonists, pioglitazone on metabolic abnormalities in a patient with Köbberling type of FPLD without any adverse side effects. A large series of pioglitazone treatment cases should therefore be studied to elucidate the efficacy of this treatment regimen for genetically different types of FPLD.

AB - Complex genotype/phenotype relationships have been reported in congenital partial lipodystrophy. The patient was a 33-year-old female with progeroid features and hyperinsulinemia, insulin resistance associated with metabolic abnormalities including not only diabetes, hypertension, fatty liver, hirsutism, polycystic ovary syndrome, acanthosis nigricans, as well as a also short stature and a sensorineural deafness. Her body fat distribution was the characteristic pattern of "partial lipodystrohy" which showed a generalized subcutaneous fat loss, but an excessive accumulation of intraabdominal fat Low fasting plasma leptin and adiponectin levels were observed. No Lamin A/C or PPARγ mutations were identified. Normal insulin receptor binding and an abnormality in the post IRS-1 signaling pathway were found by a primary fibroblast culture. She was tentatively diagnosed to have either the sporadic Köbberling type or a variety of congenital [familial]partial lipodystropy (referred to in publications as the "FPLD1"). We herein present our long-term experience of treating this case with pioglitazone. Both subcutaneous and visceral fat increased following this treatment in addition the leptin and adiponectin levels also increased. An increased insulin sensitivity and improvements in both glucose intolerance and liver dysfunction were also observed during the follow-up period. This case therefore demonstrated the benefits of PPARγ-agonists, pioglitazone on metabolic abnormalities in a patient with Köbberling type of FPLD without any adverse side effects. A large series of pioglitazone treatment cases should therefore be studied to elucidate the efficacy of this treatment regimen for genetically different types of FPLD.

UR - http://www.scopus.com/inward/record.url?scp=54149083384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54149083384&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:54149083384

VL - 51

SP - 849

EP - 860

JO - Journal of the Japan Diabetes Society

JF - Journal of the Japan Diabetes Society

SN - 0021-437X

IS - 9

ER -